Virbac said on Thursday that it expected like-for-like sales growth of between 4% and 6% in 2025, and an adjusted EBIT ratio on a par with 2024, following a 10.5% rise in fourth-quarter sales.

The animal health specialist had previously forecast sales growth of between 7% and 9% for 2024, and an adjusted EBIT ratio of around 16%.

Group sales for the fourth quarter totaled 355.4 million euros, up 10.5% at actual exchange rates.

"The impact of the Sasaeah acquisition is expected to represent 1pt of additional growth in 2025", says the press release.

Virbac also reaffirms its objective of achieving an adjusted EBIT ratio of 20% by 2030.

(Written by Noémie Naudin, edited by Augustin Turpin)